Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet